| Somatotropin deficiency

Skytrofa vs Humatrope

Side-by-side clinical, coverage, and cost comparison for somatotropin deficiency.

Deep comparison between: Skytrofa vs Humatrope with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsHumatrope has a higher rate of injection site reactions vs Skytrofa based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Humatrope but not Skytrofa, including UnitedHealthcare

Category

Skytrofa

Humatrope

At A Glance

RouteSC injection

FrequencyOnce weekly

ClassPegylated growth hormone prodrug

RouteSC injection

FrequencyDaily

ClassRecombinant human growth hormone

Indications

Somatotropin deficiency

Somatotropin deficiency
Turner Syndrome
Short Stature Homeobox Deficiency
Growth retardation

Dosing

Somatotropin deficiency (pediatric) 0.24 mg/kg body weight SC once weekly; individualize and titrate based on response.

Somatotropin deficiency (adult) Starting dose 0.7-2.1 mg SC once weekly based on age and concomitant oral estrogen use; titrate monthly based on clinical response and/or IGF-1 concentration; maximum 6.3 mg once weekly.

Somatotropin deficiency (pediatric) 0.18 mg/kg/week to 0.3 mg/kg/week divided into equal doses given 6 or 7 days per week by SC injection.

Somatotropin deficiency (adult) Non-weight based: initiate at approximately 0.2 mg/day (range 0.15-0.3 mg/day), increase every 1-2 months by 0.1-0.2 mg/day per patient requirements; weight-based (not for obese patients): initiate at 0.006 mg/kg/day up to 0.0125 mg/kg/day; daily SC injection.

Turner Syndrome Up to 0.375 mg/kg/week divided into equal doses given 6 or 7 days per week by SC injection.

Short Stature Homeobox Deficiency 0.35 mg/kg/week (0.05 mg/kg/day) by SC injection.

Growth retardation Idiopathic Short Stature: up to 0.37 mg/kg/week; Small for Gestational Age: up to 0.47 mg/kg/week; divided into equal doses given 6 or 7 days per week by SC injection.

Contraindications

Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Hypersensitivity to somatropin or any excipient in SKYTROFA
Closed epiphyses in pediatric patients
Active malignancy
Active proliferative or severe non-proliferative diabetic retinopathy
Prader-Willi syndrome in pediatric patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment

Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Prader-Willi syndrome in pediatric patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
Active malignancy
Known hypersensitivity to somatropin or any excipient in HUMATROPE
Active proliferative or severe non-proliferative diabetic retinopathy
Closed epiphyses in pediatric patients

Drug Interactions

196View drug interactions

267View drug interactions

Adverse Reactions

Most common (>= 5%) Viral infection, pyrexia, cough, nausea and vomiting, hemorrhage, diarrhea, abdominal pain, arthralgia and arthritis (pediatric); edema, central hypothyroidism (adult)

Serious Increased mortality in acute critical illness, severe hypersensitivity, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, progression of preexisting scoliosis, pancreatitis, lipoatrophy, sudden death in Prader-Willi syndrome pediatric patients

Postmarketing Severe systemic hypersensitivity reactions including anaphylactic reactions and angioedema, osteonecrosis in pediatric patients

Most common (>=5%) Edema, arthralgia, paresthesia, myalgia, pain, peripheral edema, headache, hypertension, rhinitis, back pain (adults); hypothyroidism, allergic reaction, arthralgia, bone disorder, injection site pain (pediatric GHD).

Serious Increased mortality in acute critical illness, fatalities in Prader-Willi syndrome, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, severe hypersensitivity, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, pancreatitis, lipoatrophy.

Postmarketing Anaphylactic reactions, angioedema, increase in size or number of cutaneous nevi, gynecomastia, pancreatitis, new-onset type 2 diabetes mellitus, osteonecrosis, leukemia.

Pharmacology

Lonapegsomatropin-tcgd is a pegylated prodrug of somatropin that releases active growth hormone via autocleavage of the TransCon linker; somatropin binds the growth hormone (GH) receptor, driving IGF-1-mediated and direct effects including chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, lipolysis, and skeletal growth at the epiphyses of long bones.

Somatropin is a recombinant human growth hormone that binds dimeric GH receptors on target tissue cell membranes, triggering intracellular signal transduction and induction of GH-dependent proteins (IGF-1, IGFBP-3, acid-labile subunit), with direct and IGF-1-mediated effects including stimulation of chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, and lipolysis, thereby promoting skeletal and linear growth in pediatric patients with GH deficiency.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Skytrofa